OTCMKTS:BNOEF Bionomics (BNOEF) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free BNOEF Stock Alerts $0.0034 0.00 (-43.33%) (As of 09/19/2023) Add Compare Share Share Today's Range$0.0034▼$0.003450-Day Range N/A52-Week Range$0.00▼$0.06Volume22,900 shsAverage Volume140,299 shsMarket Capitalization$4.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Bionomics alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Bionomics Stock (OTCMKTS:BNOEF)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More BNOEF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNOEF Stock News HeadlinesApril 17, 2024 | bbc.co.ukChilli beef udon noodlesMarch 21, 2024 | msn.comBionomics to advance non-SSRI PTSD candidate to Phase IIIApril 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. January 5, 2024 | tmcnet.comBionomics to Present at Biotech Showcase™ 2024December 30, 2023 | bbc.co.ukPeter Bone MP loses seat as recall petition triggers by-electionDecember 6, 2023 | msn.comBionomics presents data on reliability of the Subjective Units of Distress ScaleOctober 16, 2023 | markets.businessinsider.comBionomics Secures Buy Rating Amidst Promising BNC210 Developments and Potential Market Entry AdvantageSeptember 29, 2023 | msn.comBionomics stock rockets 415% on positive study for PSTD drugApril 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. September 28, 2023 | proactiveinvestors.comBionomics shares soar almost 400% after positive phase IIb results from PTSD treatmentSeptember 28, 2023 | marketwatch.comBionomics Shares Take Flight on Positive PTSD Study ResultsSeptember 28, 2023 | marketwatch.comBionomics Shares Rally Premarket on Phase 2B PTSD Study SuccessSeptember 28, 2023 | markets.businessinsider.comBionomics: Phase 2b ATTUNE Trial With BNC210 Meets Primary Endpoint - Quick FactsSeptember 28, 2023 | msn.comBionomics announces positive results in trial of treatment for PTSDSeptember 26, 2023 | ftw.usatoday.comJay Norvell's beef with Deion Sanders and Colorado is so good for college footballSeptember 14, 2023 | finance.yahoo.comBionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSDJuly 9, 2023 | usatoday.comMike Trout suffers broken hamate bone, likely out six to eight weeksApril 27, 2023 | finance.yahoo.comBionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)March 10, 2023 | markets.businessinsider.comPositive Report for Bionomics (BNOX) from Evercore ISIMarch 8, 2023 | finance.yahoo.comBionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)March 3, 2023 | msn.comBears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' NowFebruary 10, 2023 | finance.yahoo.comBionomics Limited (BNOEF) Stock Historical Prices & Data - Yahoo FinanceDecember 15, 2022 | marketwatch.comBionomics Names Spyridon Papapetropoulos as President, CEODecember 15, 2022 | finance.yahoo.comBionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive OfficerNovember 21, 2022 | nz.finance.yahoo.comBionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United StatesNovember 17, 2022 | marketwatch.comBionomics Shares Drop 18% After ADS Offering PricesOctober 18, 2022 | seekingalpha.comBionomics receives R&D tax incentive refund for FY22 of A$4.6MSee More Headlines Receive BNOEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Noncommercial research organizations Sub-IndustryN/A Current SymbolOTCMKTS:BNOEF CUSIPN/A CIK1191070 Webwww.bionomics.com.au Phone(188) 150-7400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,309,557,000Free FloatN/AMarket Cap$4.45 million OptionableNot Optionable Beta1.86 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Adrian Hinton BEC (Age 70)F.C.A., Financial Controller Comp: $205.67kDr. Spyridon Papapetropoulos M.D. (Age 50)Ph.D., CEO, Pres & Director Mr. Timothy M. Cunningham CPA (Age 60)CPA, M.B.A., Chief Financial Officer Prof. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical NeuroscienceDr. Julie Kerner Ph.D.Sr. VP of Bus. OperationsDr. Atul R. Mahableshwarkar DFAPAM.D., Acting Chief Medical OfficerMs. Suzanne Irwin B.Com.FCIS, Company Sec.More ExecutivesKey CompetitorsPortage BiotechNASDAQ:PRTGExicureNASDAQ:XCURLipella PharmaceuticalsNASDAQ:LIPONexImmuneNASDAQ:NEXISharps TechnologyNASDAQ:STSSView All Competitors BNOEF Stock Analysis - Frequently Asked Questions How have BNOEF shares performed in 2024? Bionomics' stock was trading at $0.0034 at the start of the year. Since then, BNOEF stock has increased by 0.0% and is now trading at $0.0034. View the best growth stocks for 2024 here. How do I buy shares of Bionomics? Shares of BNOEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BNOEF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
